doi: 10.1016/s0361-9230(03)00185-0.
Standardization and statistical approaches to therapeutic trials in the R6/2 mouse
Affiliations
- PMID: 13679245
- DOI: 10.1016/s0361-9230(03)00185-0
Item in Clipboard
Standardization and statistical approaches to therapeutic trials in the R6/2 mouse
Brain Res Bull.
.
Abstract
The R6/2 mouse is the most widely used animal model of Huntington's disease (HD), a genetic disorder causing movement disorders, personality changes, dementia, and premature death, for which there is currently no effective therapy. Use of animal models to assess novel therapeutic approaches to HD is currently a major focus of research. Progress in this field will depend upon careful standardization of experimental protocols, and a sophisticated statistical approach. Here we investigate the sources of phenotypic variability in R6/2, and make recommendations for the future use of such models in therapeutic trials.
Similar articles
-
Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease.Exp Neurol. 2018 Apr;302:112-128. doi: 10.1016/j.expneurol.2018.01.001. Epub 2018 Jan 6. Exp Neurol. 2018. PMID: 29309751
-
Longitudinal analysis of the electroencephalogram and sleep phenotype in the R6/2 mouse model of Huntington's disease.Brain. 2013 Jul;136(Pt 7):2159-72. doi: 10.1093/brain/awt132. Brain. 2013. PMID: 23801738
-
A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease.J Neurophysiol. 2012 Jan;107(2):677-91. doi: 10.1152/jn.00762.2011. Epub 2011 Nov 9. J Neurophysiol. 2012. PMID: 22072510 Free PMC article.
-
Experimental therapeutics in Huntington's disease: are models useful for therapeutic trials?Curr Opin Neurol. 2003 Aug;16(4):465-70. doi: 10.1097/01.wco.0000084223.82329.bb. Curr Opin Neurol. 2003. PMID: 12869804 Review.
-
The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies.NeuroRx. 2005 Jul;2(3):447-64. doi: 10.1602/neurorx.2.3.447. NeuroRx. 2005. PMID: 16389308 Free PMC article. Review.
Cited by
-
HDAC4-myogenin axis as an important marker of HD-related skeletal muscle atrophy.PLoS Genet. 2015 Mar 6;11(3):e1005021. doi: 10.1371/journal.pgen.1005021. eCollection 2015 Mar. PLoS Genet. 2015. PMID: 25748626 Free PMC article.
-
Presymptomatic Targeted Circuit Manipulation for Ameliorating Huntington's Disease Pathogenesis.bioRxiv [Preprint]. 2024 Jul 24:2024.07.24.604946. doi: 10.1101/2024.07.24.604946. bioRxiv. 2024. PMID: 39091860 Free PMC article. Preprint.
-
BDNF may play a differential role in the protective effect of the mGluR2/3 agonist LY379268 on striatal projection neurons in R6/2 Huntington's disease mice.Brain Res. 2012 Sep 14;1473:161-72. doi: 10.1016/j.brainres.2012.07.026. Epub 2012 Jul 20. Brain Res. 2012. PMID: 22820300 Free PMC article.
-
Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease.PLoS One. 2009 Nov 30;4(11):e8025. doi: 10.1371/journal.pone.0008025. PLoS One. 2009. PMID: 19956633 Free PMC article.
-
Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington's disease.PLoS One. 2011;6(6):e20696. doi: 10.1371/journal.pone.0020696. Epub 2011 Jun 3. PLoS One. 2011. PMID: 21677773 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
